IOL Chemicals secures China NMPA nod for Clopidogrel API, expanding into 10+ export regions.
IOLCP receives Chinese regulatory approval for its cardiovascular API, Clopidogrel Bisulfate, paving the way for high-volume exports to a major global market.
Read the full articleYou might also wanna read
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing
biopharmadive.com·1mo ago恒瑞医药回应“双艾”组合再次延迟批准上市：未涉及产品安全性及有效性
恒瑞医药公告公司收到美国食品药品监督管理局关于注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请的完整回复信。这也���“双艾”组合第三次被FDA延迟批准上市。对此，恒瑞医药回应称，“稳步推进国际化是公司的长期发展战略，公司多项创新
Understanding Heterogeneous Drug Procurement Behaviour of Healthcare Institutions Under Pooled Procurement: Evidence From China
Background While the overall impact of pooled drug procurement on drug procurement has been evaluated, little is known about how healthcare
Study: Clopidogrel Monotherapy Linked to Lower MACE and Bleeding Risks vs. Aspirin After PCI
Clopidogrel monotherapy was associated with lower risks of major adverse cardiovascular events (MACE) and major bleeding compared with aspir
acc.org·17d ago
麦科医药MT1002完成Ib/II期首例入组，卒中“双管线”布局加速推进
7月3日，麦科医药-B（02335.HK）公告称，其自主研发的急性缺血性卒中管线MT1002的Ib/II期临床试验完成首例患者入组。这是该公司6月24日登陆港交所后，核心管线推进的又一实质性进展。MT1002为一款凝血因子II与GPIIb/IIIa双靶点拮抗剂，兼具抗凝与抗血小板
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
Conditions : Systemic Lupus Erythematosus Interventions : Combination Product: Anifrolumab: SC formulation via AI; Combination Product: Anif
Comments
Sign in to join the conversation.
No comments yet. Be the first.